Development Agreement [Amendment No. 4] and Manufacturing and Supply Agreement [Amendment No. 1] - Janssen Pharmaceutica International, Medisorb Technologies International and Alkermes Controlled Therapeutics Inc. II
FOURTH AMENDMENT TO DEVELOPMENT AGREEMENT
FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT
This Agreement shall be the Fourth Amendment to the Development Agreement by and
between Janssen Pharmaceutica International, a division of Cilag International
AG, having its place of business in CH-6300 Zug, Switzerland ("JANSSEN") and
Medisorb Technologies International, A Delaware limited partnership
("Medisorb"), which agreement has in the meantime been duly assigned from
Medisorb to Alkermes Controlled Therapeutics Inc. II, a company organized and
existing under the laws of the Commonwealth of Pennsylvania, 64 Sidney Street,
Cambridge, MA 02139-4136, U.S.A. ("ACT II") by a deed of assignment dated. March
1, 1996.
This Agreement shall also be the First Amendment to the Manufacturing and Supply
Agreement by and between JPI PHARMACEUTICA INTERNATIONAL, a division of Cilag AG
International Zug, a company duly organized and existing under the laws of
Switzerland, having its principal office in CH-6300 Zug, Kollerstrasse 38,
Switzerland (hereinafter referred to as "JPI"), and JANSSEN PHARMACEUTICA Inc.,
1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA (hereinafter referred to
as "JANSSEN US") and ACT II, which agreement has since been duly transferred
from JANSSEN PHARMACEUTICA INC. TO JANSSEN PHARMACEUTICA PRODUCTS, L.P. (JPI and
JANSSEN US collectively referred to herein as "JANSSEN").
WHEREAS JANSSEN and ACT II desire to amend certain terms of the Development
Agreement and the Manufacturing and Supply Agreement with respect to the
ownership of certain capital equipment.
NOW THEREFORE, the parties agree to amend the Development Agreement and the
Manufacturing and Supply Agreement as follows:
1. Notwithstanding the provisions of Section 4 of the SECOND AMENDMENT to the
Development Agreement and Section 2.2 of the Manufacturing and Supply
Agreement, JANSSEN agrees to sell to ACT II and ACT II agrees to purchase
from JANSSEN the equipment described on Exhibit A, attached hereto and
made a part hereof (the "Equipment") for good and valuable consideration
of $1.00 (one U.S. dollar).
2. THE EQUIPMENT IS SOLD "WHERE IS; AS IS" WITHOUT ANY REPRESENTATION OR
WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, ANY REPRESENTATION OR WARRANTY AS TO THE DESIGN, QUALITY OR
CONDITION OF THE EQUIPMENT, ANY WARRANTY OF MERCHANTABILITY OR FITNESS OF
THE
<PAGE>
EQUIPMENT FOR ANY PARTICULAR PURPOSE OR AS TO THE OTHER MATTER RELATING TO
THE EQUIPMENT OR ANY PART THEREOF. ACT II CONFIRMS THAT IT HAS SELECTED
THE EQUIPMENT ON THE BASIS OF ITS OWN JUDGMENT AND EXPRESSLY DISCLAIMS
RELIANCE UPON ANY STATEMENTS, REPRESENTATIONS OR WARRANTIES MADE BY
JANSSEN.
3. ACT II HEREBY ASSUMES AND RELEASES JANSSEN FROM ANY AND ALL CLAIMS ARISING
FROM THE USE OR OPERATION OF THE EQUIPMENT (OR THE FAILURE TO OPERATE OR
OTHER IMPROPER FUNCTIONING OF THE EQUIPMENT), OR ANY PART THEREOF, FROM
AND AFTER THE DATE HEREOF AND HEREBY INDEMNIFIES AND HOLDS HARMLESS
JANSSEN FOR ANY AND ALL DAMAGES RESULTING FROM THE USE OR OPERATION OF THE
EQUIPMENT (OR THE FAILURE TO OPERATE OR OTHER IMPROPER FUNCTIONING OF THE
EQUIPMENT), OR ANY PART THEREOF, FROM AND AFTER THE DATE HEREOF,
INCLUDING, WITHOUT LIMITATION, ALL INCIDENTAL OR CONSEQUENTIAL DAMAGES FOR
LOSS OF REVENUE OR PROFIT, LOSS OF USE OF THE EQUIPMENT, DOWNTIME COSTS OR
COST OF ANY SUBSTITUTE EQUIPMENT.
4. THIS AMENDMENT SHALL BE EFFECTIVE AS OF DECEMBER 20, 2000.
WITNESS, the signature of all parties hereto by their duly authorized officers.
JANSSEN PHARMACEUTICA INTERNATIONAL
Represented by CILAG AG INTERNATIONAL
CILAG AG INTERNATIONAL
Landis + Gyr-Strasse 1
CH-6300 Zug
/s/ E. Rombouts /s/ H. Schmid
---------------------- -----------------------
(title) EXECUTIVE DIRECTOR OPERATIONS (title) GENERAL MANAGER
E. ROMBOUTS H. SCHMID
ALKERMES CONTROLLED THERAPEUTICS INC. II
/s/ James Frates /s/ Michael Landine
---------------------- ----------------------
(title) VICE PRESIDENT (title) VICE PRESIDENT
JANSSEN PHARMACEUTICA PRODUCTS, L.P.
/s/ Michael Chester
---------------------- -----------------------
(title) (title) SECRETARY
<PAGE>
EXHIBIT A
[***]
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.